136 related articles for article (PubMed ID: 24752862)
1. Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation.
Alladi S; Shastri NR
Arch Pharm Res; 2015; 38(5):801-12. PubMed ID: 24752862
[TBL] [Abstract][Full Text] [Related]
2. Modulating drug release profiles by lipid semi solid matrix formulations for BCS class II drug--an in vitro and an in vivo study.
M K; Sistla R; Shastri NR
Drug Deliv; 2015 May; 22(3):418-26. PubMed ID: 24471823
[TBL] [Abstract][Full Text] [Related]
3. Utilization of spray drying technique for improvement of dissolution and anti-inflammatory effect of Meloxicam.
Shazly G; Badran M; Zoheir K; Alomrani A
Pak J Pharm Sci; 2015 Jan; 28(1):103-11. PubMed ID: 25553688
[TBL] [Abstract][Full Text] [Related]
4. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
Agarwal V; Alayoubi A; Siddiqui A; Nazzal S
Drug Dev Ind Pharm; 2013 Nov; 39(11):1681-9. PubMed ID: 23072611
[TBL] [Abstract][Full Text] [Related]
5. Self nanoemulsifying granules (SNEGs) of meloxicam: preparation, characterization, molecular modeling and evaluation of in vivo anti-inflammatory activity.
Parekh VJ; Desai ND; Shaikh MS; Shinde UA
Drug Dev Ind Pharm; 2017 Apr; 43(4):600-610. PubMed ID: 28005437
[TBL] [Abstract][Full Text] [Related]
6. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
7. Effect of solubility enhancement on nasal absorption of meloxicam.
Horváth T; Ambrus R; Völgyi G; Budai-Szűcs M; Márki Á; Sipos P; Bartos C; Seres AB; Sztojkov-Ivanov A; Takács-Novák K; Csányi E; Gáspár R; Szabó-Révész P
Eur J Pharm Sci; 2016 Dec; 95():96-102. PubMed ID: 27260088
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and enhancement of physical stability of semi-solid dispersions containing piroxicam into hard gelatin capsules.
Karataş A; Bekmezci S
Acta Pol Pharm; 2013; 70(5):883-97. PubMed ID: 24147368
[TBL] [Abstract][Full Text] [Related]
9. Photophysical studies of oxicam group of NSAIDs: piroxicam, meloxicam and tenoxicam.
Banerjee R; Chakraborty H; Sarkar M
Spectrochim Acta A Mol Biomol Spectrosc; 2003 Apr; 59(6):1213-22. PubMed ID: 12659890
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the in-vitro dissolution and in-vivo oral bioavailability of silymarin from liquid-filled hard gelatin capsules of semisolid dispersion using Gelucire 44/14 as a carrier.
Hussein A; El-Menshawe S; Afouna M
Pharmazie; 2012 Mar; 67(3):209-14. PubMed ID: 22530301
[TBL] [Abstract][Full Text] [Related]
11. Effect of lipid molecule headgroup mismatch on non steroidal anti-inflammatory drugs induced membrane fusion.
Mondal Roy S; Sarkar M
Langmuir; 2011 Dec; 27(24):15054-64. PubMed ID: 21999838
[TBL] [Abstract][Full Text] [Related]
12. Forced and long-term degradation assays of tenoxicam, piroxicam and meloxicam in river water. Degradation products and adsorption to sediment.
Jiménez JJ; Muñoz BE; Sánchez MI; Pardo R
Chemosphere; 2018 Jan; 191():903-910. PubMed ID: 29145135
[TBL] [Abstract][Full Text] [Related]
13. Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies.
Shende PK; Gaud RS; Bakal R; Patil D
Colloids Surf B Biointerfaces; 2015 Dec; 136():105-10. PubMed ID: 26364091
[TBL] [Abstract][Full Text] [Related]
14. Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol.
Karataş A; Yüksel N; Baykara T
Farmaco; 2005 Sep; 60(9):777-82. PubMed ID: 16084514
[TBL] [Abstract][Full Text] [Related]
15. Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations.
Verma MM; Kumar MT; Balasubramaniam J; Pandit JK
Boll Chim Farm; 2003 Apr; 142(3):119-24. PubMed ID: 12806831
[TBL] [Abstract][Full Text] [Related]
16. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network.
Xu S; Hermanson DJ; Banerjee S; Ghebreselasie K; Clayton GM; Garavito RM; Marnett LJ
J Biol Chem; 2014 Mar; 289(10):6799-6808. PubMed ID: 24425867
[TBL] [Abstract][Full Text] [Related]
17. Preparation of a solid dispersion by a dropping method to improve the rate of dissolution of meloxicam.
Bashiri-Shahroodi A; Nassab PR; Szabó-Révész P; Rajkó R
Drug Dev Ind Pharm; 2008 Jul; 34(7):781-8. PubMed ID: 18612916
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical characterization of meloxicam-mannitol binary systems.
Nassab PR; Rajkó R; Szabó-Révész P
J Pharm Biomed Anal; 2006 Jun; 41(4):1191-7. PubMed ID: 16621418
[TBL] [Abstract][Full Text] [Related]
19. Preparation and in vitro characterization of a semi-solid dispersion of flurbiprofen with Gelucire 44/14 and Labrasol.
Soliman MS; Khan MA
Pharmazie; 2005 Apr; 60(4):288-93. PubMed ID: 15881610
[TBL] [Abstract][Full Text] [Related]
20. Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?
Jin C; Zhao C; Shen D; Dong W; Liu H; He Z
J Pharm Pharmacol; 2018 Feb; 70(2):250-258. PubMed ID: 29193077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
